Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype

Is anti–programmed cell death 1 therapy effective and safe as first-line therapy in patients with advanced melanoma predominantly of acral subtype?In this phase 3 randomized clinical trial of 256 patients with advanced melanoma (160 acral subtype [62.7%]), toripalimab as first-line therapy significantly improved blinded independent central review–assessed progression-free survival compared with dacarbazine with an acceptable safety profile.Toripalimab could be used as a new first-line treatment option for advanced melanoma, particularly where acral cutaneous melanoma is the predominant subtype.

Corresponding Author: Jun Guo, MD, PhD, Department of Melanoma and Sarcoma, Peking University Cancer Hospital guoj307@126.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.